Get the Stockscreener App
182.34
1.33%
-2.45
After Hours:
182.34
Charles River Laboratories International Inc stock is traded at $182.34, with a volume of 1.03M.
It is down -1.33% in the last 24 hours and up +20.88% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$184.79
Open:
$188.81
24h Volume:
1.03M
Relative Volume:
1.18
Market Cap:
$8.78B
Revenue:
$4.03B
Net Income/Loss:
$-182.84M
P/E Ratio:
-48.49
EPS:
-3.7603
Net Cash Flow:
$391.29M
1W Performance:
-2.12%
1M Performance:
+20.88%
6M Performance:
-6.96%
1Y Performance:
+25.71%
1-Day Range:
$181.72
$191.34
1-Week Range:
$181.72
$191.34
52-Week Range:
$143.06
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
182.34 | 9.08B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
461.69 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.76 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
546.09 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
124.33 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.00 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
LH vs. CRL: Which Stock Is the Better Value Option? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories Stock (US1591881009): shares in focus after recent earnings and valuation - AD HOC NEWS
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs (CRL) Pulled Back Due to AI Disruption Fears - Insider Monkey
Top Charles River Laboratories International (CRL) Competitors 2026 - MarketBeat
Convert Charles River Laboratories International, Inc. (CRL) to New Taiwan dollar (TWD) - Crypto.com
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Recovery And Conflicting Fair Value Signals - simplywall.st
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Incyte (INCY) and Pfizer (PFE) - The Globe and Mail
Charles River (NYSE: CRL) director James C. Foster reports 366,722-share gift and trust transfers - Stock Titan
CRL (CRL) CEO shifts 6,772 shares via bona fide gifts, keeps large stake - Stock Titan
Charles River (NYSE: CRL) exec reports 3,058-share stock gifts and positions - Stock Titan
RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL) - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MSN
CRL Q1 2026 Earnings: EPS Surpasses Estimates, Stock Retreats Despite Profit BeatEstimate Uncertainty - newsline.com
Charles River Laboratories (CRL) Slips 2.4% as Key Support Levels LoomSwing Entry Signals - newsline.com
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Can Charles River’s Portfolio Divestitures and “Pathway to Purpose” Strategy Reframe the CRL Investment Narrative? - simplywall.st
Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says - marketscreener.com
Assessing Charles River Laboratories (CRL) Valuation After Mixed Returns And Contrasting Undervaluation Signals - Yahoo Finance
Charles River (CRL) director awarded 422 restricted stock units as fees - Stock Titan
CRL: New strategy targets margin gains, tech integration, and growth, with DSA momentum building - TradingView
Charles River Laboratories International Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow (NYSE:CRL) 2026-06-03 - Seeking Alpha
Charles River Laboratories International Inc (CRL) Shares Fall 4 - GuruFocus
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRL (CRL) CFO Glenn Coleman receives 6,640-share equity grant at $180.71 - Stock Titan
CRL (NYSE: CRL) CIO receives stock grant; shares withheld for taxes - Stock Titan
Charles River (NYSE: CRL) EVP awarded 5,257 shares, 979 withheld - Stock Titan
CRL (NYSE: CRL) SVP Michael Knell awarded 1,837 shares, 200 used for tax withholding - Stock Titan
Charles River (NYSE: CRL) CEO awarded shares, withholds stock to pay tax - Stock Titan
James C. Foster (CRL) records tax-withholding share disposition and updates indirect holdings - Stock Titan
Charles River (NYSE: CRL) EVP gets 5,135-share award with tax withholding - Stock Titan
Charles River (NYSE: CRL) executive reports stock grant and tax withholding - Stock Titan
CRL: Operational efficiency, innovation, and portfolio focus drive growth and resilience - TradingView
CRL: Modernization, AI, and NAMs drive growth and margin expansion, with renewed DSA momentum - TradingView
Charles River Laboratories International Inc at William Blair Growth Stock Conference Transcript - GuruFocus
Charles River Shareholder Notice - TMX Newsfile
Charles River Laboratories to Present at William Blair and Jefferies Conferences 2026 - BioSpace
Charles River Laboratories (CRL) to Present at Key Investor Conf - GuruFocus
Charles River Laboratories to Present at William Blair and Jefferies Conferences - pharmiweb.com
CLSA upgrades Charles River Laboratories International (CRL) - MSN
Charles River Laboratories (CRL) Slides Slightly, Holds Near Key ResistanceMarket Cap Weight - thelegaladvocate.com
Charles River Laboratories Hits Day High with 10.24% Surge in Stock Price - Markets Mojo
CLSA upgrades Charles River Labs stock rating on regulatory outlook - Investing.com UK
CLSA upgrades Charles River Labs stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
[Form 4] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Insider Trading Activity - Stock Titan
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):